Stay updated on Pembrolizumab Combo vs. Placebo in mCRPC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo vs. Placebo in mCRPC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo vs. Placebo in mCRPC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the context of Medical and healthcare-related publications and documentation.
    Difference
    0.3%
    Check dated 2024-06-06T14:32:13.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 6 to 7, indicating an update in the number of versions of the study record for the clinical trial. This change likely reflects the addition of a new version or update to the existing documentation related to the study of Pembrolizumab (MK-3475) in metastatic castration-resistant prostate cancer.
    Difference
    0.3%
    Check dated 2024-05-22T21:11:52.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T22:43:19.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo vs. Placebo in mCRPC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo vs. Placebo in mCRPC Clinical Trial page.